Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Avera and Avera Health Plans transitioned to a new combined patient and member portal as of May 30, 2026. If you haven’t already, create an account and reset your proxy access. Learn how to sign up at Avera.org/MyChart.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (11)

Showing 1-10 of 11

Sorted By:

A-Z
Z-A

Previous Next

C6461003: AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
PH 3 STUDY TO EVAL PF-08634404 IN COMBINATION W/ CHEMOTHERAPY VS BEVACIZUMAB IN COMBINATION W/ CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS W/ METASTATIC COLORECTAL CANCER
CABL001J1US01 (ASC4REAL-2): A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
A Real-world CML Pt Disease Registry to Describe Pt Experience & Clinical Outcomes Among Pts W/ CML Receiving Approved 1st or 2nd Line TKI Therapy
CO46274:A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS RIBOCICLIB PLUS FULVESTRANT VERSUS PLACEBO PLUS RIBOCICLIB PLUS FULVESTRANT IN PATIENTS WITH ENDOCRINE-RESISTANT HORMONE-RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH CHROMOSOME 8P LOSS AND WITHOUT A PIK3CA MUTATION
Phase 2 study evaluating the efficacy and safety of Inavaolisib + Ribociclib + Fulvestrant vs Placebo +Ribociclib + Fulvestrant in Pts with Advanced Breast Cancer
D9803C00001 CLARITY-Gastric02: A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Ph 3 Study of Sonesitatug vedotin in Combination w/Capecitabine w/wo Rilvegostomig in 1st line Claudin18.2-positive,HER2-, Adv/Met Gastric,GEJ,orEsophageal Adenocarcinoma
Faeth_FTH-PIK-201: An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer
Ph 2 Trial Evaluating Sapanisertib&Serabelisib (PIKTOR) w/Paclitaxel & Substudy Eval. PIKTOR w/Paclitaxel + Insulin-Suppressing Diet, in Pts w/ Adv/Rec Endometrial Cancer
INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
A RPhase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With/Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
MK5684-003: A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
Ph 3 Randomized, Open-label Study of MK-5684 vs Alternative Abiraterone Acetate or Enzalutamide in pts w/ mCRPC Prev. Treated w/ NHA) & Taxane-based Chemotherapy
MK5684-004: A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA) (Enrollment paused 06Aug2025)
Ph 3 Study of MK-5684 vs Alt.Abiraterone Acetate or Enzalutamide in Pts w/ mCRPC) that Progressed On /After Prior Treatment With One Next-generation Hormonal Agent (NHA)
NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab Versus Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
Ph 3 Study of Induction Pembro & Chemotherapy Followed by Chemoradiation & Pembro vs Chemoradiation & Pembro Both Followed by Pembro for High Risk Local/Adv Cervical CA
RMC-6236-401: Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib
EAP provides daraxonrasib to eligible patients with previously treated metastatic PDAC, with no alternative therapy and not able to participate in a daraxonrasib trial

Previous Next